Mizuho lowered the firm’s price target on Adverum Biotechnologies (ADVM) to $5.50 from $12 and keeps an Outperform rating on the shares.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ADVM:
- Adverum Biotechnologies price target raised to $4 from $3 at RBC Capital
- Adverum Biotechnologies’ Phase 3 Study on Ixo-vec: A Potential Game-Changer for AMD Treatment
- Adverum Biotechnologies downgraded to Neutral from Buy at Chardan
- M&A News: Eli Lilly’s (LLY) $262M Acquisition of Adverum Bolsters Gene Therapy Push
- Adverum Biotechnologies downgraded to Hold from Buy at Truist